Trambas Christina, Lu Zhong, Yen Tina, Sikaris Ken
1 Melbourne Pathology, Collingwood, Australia.
2 Department of Medicine, Monash University, Clayton, Australia.
Ann Clin Biochem. 2018 Mar;55(2):216-226. doi: 10.1177/0004563217707783. Epub 2017 Jun 29.
Background Biotin interference in streptavidin-based immunoassays causes widespread analytical distortions that may lead to clinical confusion, inappropriate patient management and, ultimately, adverse events. Its prevalence has increased recently due to the increased use of high-dose biotin therapy in specific patient groups (notably multiple sclerosis) and possibly the general community. Methods We have developed a method to deplete biotin from samples using the streptavidin-coated magnetic microparticles that are a component of most susceptible assays. Results We show that high concentrations of spiked biotin can be adequately depleted from serum using this approach, and that gross biochemical derangements can be restored to normality. We also show that biotin in samples derived from multiple sclerosis patients receiving 300 mg biotin daily can be adequately depleted to remove associated analytical interference and restore normal results. The method is applicable to competitive and sandwich immunoassays and importantly, because it does not change the volume of the sample, suitable for the measurement of free thyroid hormone assays. Application of the method does not significantly change the precision of measurement, and for the majority of analytes, the accuracy is not substantially altered. Conclusions Adopting this method enables laboratories to confirm biotin interference in the appropriate clinical setting. Moreover, it enables laboratories to remove the interference and report accurate and reliable results, without the need for patients to withhold beneficial therapy prior to blood tests. Until the biotin tolerance of susceptible assays is improved, our method gives laboratories a safe alternative for reporting results using streptavidin-based methods.
基于链霉亲和素的免疫测定中生物素干扰会导致广泛的分析偏差,可能引发临床困惑、不适当的患者管理,最终导致不良事件。由于特定患者群体(尤其是多发性硬化症患者)以及可能在普通人群中高剂量生物素治疗的使用增加,其发生率最近有所上升。方法:我们开发了一种方法,使用大多数易受影响测定中作为组成部分的链霉亲和素包被磁性微粒从样本中去除生物素。结果:我们表明,使用这种方法可以从血清中充分去除高浓度的添加生物素,并且严重的生化紊乱可以恢复正常。我们还表明,对于每天接受300毫克生物素的多发性硬化症患者的样本中的生物素,可以充分去除以消除相关的分析干扰并恢复正常结果。该方法适用于竞争性和夹心免疫测定,重要的是,由于它不会改变样本体积,适用于游离甲状腺激素测定。该方法的应用不会显著改变测量精度,并且对于大多数分析物,准确性也不会有实质性改变。结论:采用这种方法使实验室能够在适当的临床环境中确认生物素干扰。此外,它使实验室能够消除干扰并报告准确可靠的结果,而无需患者在血液检测前停止有益治疗。在易受影响的测定的生物素耐受性得到改善之前,我们的方法为实验室提供了一种使用基于链霉亲和素方法报告结果的安全替代方案。